AIDS Gene Therapy

Company Completes Enrollment In T Cell Gene Therapy Trial For AIDS

Published in Cancer Weekly, September 18th, 1995

Cell Genesys, Inc., Foster City, California, announced that it recently completed patient enrollment for the Phase I portion of its initial trial of anti-HIV T-cell gene therapy for AIDS.

Twenty-nine patients have entered the Phase I/II trial which began October 1994 at the U.S. National Institute of Allergy and Infectious Diseases (NIAID). The Phase II portion of this trial is expected to begin later in 1995 after review of Phase I safety results.

Cell Genesys' T-cell gene therapy is a novel therapy which involves the genetic modification of killer T cells from the human immune system for the treatment of viral infection and cancer. Company...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1995-09-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry